MAGEA10
Melanoma-associated antigen 10
Protein Summary
Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression. This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream melanoma antigen family A, 5 (MAGEA5) gene.[provided by RefSeq, Oct 2011]
- ENST00000244096
- ENSP00000244096
- ENSG00000124260
- ENST00000370323
- ENSP00000359347
- MAGE10
- CT1.10
- MAGE10
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
tissue sample | 0.48 | ||
cell line | 0.42 | ||
protein domain | 0.41 | ||
transcription factor | 0.4 | ||
disease | 0.38 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 23.19 (req: < 5)
Gene RIFs: 6 (req: <= 3)
Antibodies: 189 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 23.19 (req: >= 5)
Gene RIFs: 6 (req: > 3)
Antibodies: 189 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Term: 0
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0